Background Clinical trials are essential in neonates to evaluate scientifically the efficacy and safety of drugs. However, major specificities condition clinical research in human neonates. Objective To review specific constraints to be taken into account in neonatal research studies. Methods A review of the literature and contribution of authors' opinions was carried out. Results and conclusion Neonatal specificities that induce obstacles in neonatal studies and proposals are detailed. This review also looks at recommendations recently developed by the European Commission to promote safe and ethical research in neonatology.
Introduction
Clinical trials are essential to provide safe, effective, and evidence-based medicine. In contrast, up to 90% of drugs are used in an unauthorized and off-label manner in neonates with a greater risk of drug toxicity [1] . Actually, reserves to perform clinical trials in neonates are bound to physiological and ethical specifics. Indeed, neonatal studies encompass numerous obstacles of which the vulnerability and the incompetence of this population, the technical difficulties, the uniqueness of neonatal diseases and the frequency of emergency situations. Neonatology is a relatively new discipline that should largely benefit from clinical research, but the fragility of neonatal subjects makes them highly vulnerable to experimental interventions. That is why specific risks and limits of studies in the neonatal period must be counter-balanced by both strictly controlled, but also incited research. Recently, the European Commission has edited recommendations on clinical trials in pediatrics in a way to regulate, promote and harmonize research in the European pediatric population [2] . This paper focuses on the methodological and ethical problems specific to clinical trials in neonates.
Safety and risk
Children are not small adults and neonates are not small children. The history of clinical research is full of dramatic examples that demonstrate the uniqueness of neonatal physiology. The risk/benefits equipoise must always be considered [3, 4] .
Physiological specificity of the neonates
Neonates are the group of children from birth up to 28 days exclusive, be they preterm or term. This transitional period is characterized by the physiological immaturity of many organs or systems that could impact on the pharmacokinetics, pharmacodynamics, and finally the tolerance of drugs [5] . Cardiopulmonary changes are critical events that could influence organ functions (renal blood flow, brain perfusion, hepatic metabolism). In preterm babies, many pathological situations (such as patent ductus arteriosus or respiratory distress syndrome) can interfere with a trial protocol and have to be considered. Another aspect of neonatal specificity is brain development. Indeed, maturation of the central nervous system is a continuous process (glial multiplication) that is completed long after birth (by 1 year of age). This immaturity makes the brain more vulnerable; thus, autoregulation of the cerebral blood flow is limited. Drugs can interact with neurotransmitters and lead to long-term neurodevelopmental effects. In particular, drugs interacting with bilirubin metabolism should be carefully monitored. Renal function is also altered in neonates. Glomerular filtration is physiologically reduced. This impairment is accentuated by preterm birth (incomplete nephrogenesis before 34 weeks' post-menstrual age) or by ongoing disease or intrauterine growth retardation. Therefore, the lower renal elimination capacity of neonates has to be considered and estimated using both the post-natal and post-menstrual ages. The pharmacokinetics of drugs can also be changed by hepatic and enzymatic immaturity that altered hepatic clearance as well as glucuronidation and enterohepatic recirculation. Moreover, the immaturity of the gastrointestinal tract (high gastric pH, reduced pancreatic and biliary functions) can alter the bioavailability of orally administrated drugs and make it unpredictable. Gastrointestinal immaturity makes the preterm neonate more susceptible to necrotizing enterocolitis. Lastly, associated diseases (respiratory distress syndrome, patent ductus arteriosus, necrotizing enterocolitis or retinopathy of prematurity) and conditions (prematurity or in utero growth restriction) can independently affect the pharmacokinetics and pharmacodynamics of drugs.
Risks of clinical trials in neonates
The immaturity of neonates associated with severe diseases that require administration of multiple drugs increases the risk of iatrogenic events, drug interactions, and adverse reactions. In a recent review, Sammons and colleagues evaluated the drug toxicity, studying 739 pediatric clinical trials published over 7 years [6] . Seventy one percent of trials reported adverse events and 20% reported serious adverse events. In 11% of the trials, moderate or severe adverse drug reactions (ADR) were present. Thirteen percent of trials involved neonates, but neonatal trials were over-represented in studies with severe ADR (9 out of 35 trials). The severe ADR included apnea, hypotension, gastrointestinal hemorrhage, ototoxicity, and sepsis. Mortality was also higher in trials involving neonates, even if mortality was often linked to the natural process of the disease. In two trials in neonates, mortality was higher in the treatment group. But surprisingly, the authors noticed that only 2% of the trials had an independent safety monitoring committee, as recommended in Europe. Another peculiarity of neonatal research is the necessity for long-term follow-up for safety. Indeed, many studies have shown that early infancy is a critical window for the programming of physiological changes. We have to consider the possibility of long-term effects, in particular neurodevelopmental effects of drugs used in the neonatal period.
Pain and stress
Many studies showed that repeated or prolonged exposure to pain or stress is an independent risk factor for brain damage and neurodevelopmental impairment [7, 8] . Indeed, immature neurons and glial elements are vulnerable to apoptosis or excitotoxicity that may be favored by painful procedures. Limitation of stressing procedures (noise, light, blood sampling and investigations) must be a priority during clinical trials. Many validated non-invasive techniques (cardiac monitoring, transcutaneous measurement of pCO 2 , oxygen saturation from pulse oxymetry, cardiac and brain ultrasound) can be used to evaluate clinical parameters. Pain has to be prevented, monitored using validated scales, and adequately managed using pre-emptive treatment like sucrose or topical anesthesia. The use of an indwelling catheter (umbilical or arterio-venous catheter) has to be considered when repeated blood samples are needed.
Trial design: methodology, limits
The specificity of the neonatal period has been emphasized in the previous sections and summarized in Table 1 . The specificity of neonatal patients induces limitations in trial design that can be encompassed by methodological adaptations.
Specific institutions for specific patients
Special patients need special trials by experienced centers. These imply a specific regulation and representation of pediatric and neonatal medicine in institutional review boards and ethics committees as well as local specific institutional and administrative assistance with appropriate 
Specific methods for specific patients
Even if relative homogeneity of patients and standardization of neonatal care are marked advantages in neonatal research, studies are limited by small samples of eligible patients and by a low number of perinatal centers. These obstacles can be by-passed with the optimization of design methods. Randomized, multicenter, and blinded studies are the gold standard for the demonstration of both efficacy and safety. In this vulnerable population, size sample should be as small as possible to demonstrate efficacy with sufficient statistical power. Adaptive Bayesian sequential modeling or other models also developed in adults can be used to decrease the number of participants. Otherwise, the use of placebo has to be discussed. The use of placebo is restricted compared with studies in adults or children, but can be considered in the case of poor or questionable efficacy or safety of the commonly used treatment. In particular, in studies on analgesia, the use of placebo is not acceptable. A comparator group is ethically more acceptable and clinically more relevant even in the case of off-label use if they are the standard of care. The technique of population pharmacokinetics based on lower blood samples in a larger population is interesting to limit both blood samples and bias linked to the maturation process and inter-individual variability. Stratification by term gestation or birth weight of the trial population is often required to limit the influence of the maturation process. Many antenatal (antenatal treatment, maternal diseases) and postnatal (drugs, patent ductus arteriosus, hemodynamic and respiratory status) conditions can affect outcome and require identification and careful analysis to limit bias. Relevant primary endpoints have to be described, based on harmonized definitions and assessed using validated procedures for judgment. The complications of prematurity (bronchopulmonary dysplasia, intraventricular hemorrhage, necrotizing enterocolitis, retinopathy of prematurity), and survival are classical secondary endpoints that need to be assessed. Lastly, we underline the importance of long-term physical and neurodevelopmental follow-up to evaluate the long-term impact of drugs in this maturing population.
Specific drugs for specific patients
Iatrogenic events are more frequent in neonates. These events underline the importance of the accurate choice of formulations and route of administration. First, neonates suffer more medication errors. The implication of drugs companies is essential to provide appropriate formulations in way to limit dilutions. Second, adverse drug reactions are more frequent and more severe in neonates. Potential incompatibilities, excessive amounts of electrolytes, cutaneous or digestive tolerance must be considered. Finally, it is essential to re-adjust the dosage of drugs over time according to the actual weight and organ maturation of the neonate to maintain the best efficacy and safety.
Volume of blood samples Preterm and term neonates have restricted blood volume (80 to 90 ml/kg). Moreover, pathological conditions increase blood loss and the necessity for blood sampling. Recommendations have been applied to limit trial-related blood loss. Micro-method samples are required and limited to 2.4 ml blood per kilogram body weight for the 3% limit, over a 4-week period. Expected blood loss has to be detailed both in the trial protocol and on the parent information sheet.
Ethical issues
Ethical principles in neonatal research are expressed in the Declaration of Helsinki and based on three foundations: respect for persons, beneficence, and justice [9] .
Balance of risk and benefit
The probability of benefits and potential risks needs to be continuously balanced [10] . The neonate's interest always prevails over that of science or society. Risk is classically divided into three categories: minimal, low or minor, and high. Risk also depends on the invasiveness of the procedures and monitoring or the toxicity of the drugs. Benefit can be defined as a progress in safety or efficacy in treatment. The risk/benefit balance must take into consideration the severity of the condition/disease studied, the vulnerability of the neonates, and the expected improvement in comparison to an alternative existing treatment. Non-therapeutic experiments with benefits for the neonatal population have a limited place in neonatal research and can only be considered if they cannot be performed in older children at minimal or low risk. As in adults, risk has to be continuously monitored using a Data and Safety Monitoring Board. Independent pediatric experts are recommended.
Composition of the ethics committee
Ethics committees are needed to provide an independent opinion of the trial and of the balance of risk/benefits. The vulnerability and pharmacological peculiarities of neonates, and the complexity and frequent emergency context of neonatal situations, underline the importance of having scientific scrutiny and ethical expertise of protocols. The committees must include pediatrics physicians qualified in neonatal medicine and trained to carry out clinical research, as well as pediatric ethicists, pharmacologists or psychologists. In particular, they have to make sure that pain and stress induced by clinical research have been prevented and minimized [11] . They also require minimal blood sampling [12] .
Parental consent
As neonates can obviously never give consent themselves, the informed, voluntary, and written consent of each legal representative of the neonate is ethically and legally required prior to enrollment. This consent meets the standards required with regard to other consent. Information must be honest, adequate, and must describe the aim and nature of the study, the expected benefits or potential risks, the name of the investigators, and contact details. The consent has to be given without coercion. Sufficient time for thinking must be accorded and the possibility of revoking informed consent must be specified. Consent is a continuous process that needs time and multiple discussions during the trial. In practice, many circumstances could interfere with those consent criteria. Many concepts such as randomization can be misunderstood by parents. Emergency situations are frequent and can disturb the consent process and parent objectivity, particularly when the time available to give consent is short and diseases are life-threatening. The relationship between the parents and the physician is also complex. This relationship depends on many psychological, emotional, cultural, and social circumstances as well as the severity of the disease, which could affect their judgment and influence their reasons for consent. Otherwise, it can occasionally be hard to respect parents' decisions that seem to compromise the fundamental rights of the infant to beneficence. Clinical research in neonates points out many philosophical questions and limitations of legislation [13] [14] [15] . It is most important to obtain the best consent possible and to adjust information honestly in a continuous and dynamic process of assent [16] .
Conclusion
Authorities have now realized the importance of the development of clinical trials especially for children.
Recommendations have been made to harmonize practices all over Europe as a way of promoting safe and ethical research. Guidelines reflect positive evolutions and changes in our societies with regard to clinical research in the pediatric population. However, applying these pediatric guidelines to neonatal research is sometimes challenging. These difficulties underline the necessity for specific protective regulations on neonatal research. Let us hope that the pharmaceutical industry supports these changes.
